SSRIs do not increase risk of heart problems, study reveals

24 March 2016

Commonly-used anti-depressants known as selective serotonin reuptake inhibitors (SSRIs) do not increase the risk of cardiovascular conditions among young and middle-aged people, a new study has revealed.

Researchers at the UK’s University of Nottingham found no evidence that SSRIs are associated with an increased risk of arrhythmia or stroke/transient ischemic attack in people diagnosed as having depression between the ages of 20 to 64.

Depression is known to increase the risk of cardiovascular problems, but controversy exists as to whether antidepressants, particularly SSRIs, increase or reduce this risk.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK